Domainex's Drug Discovery Pipeline
Domainex specializes in drug discovery and has an excellent pedigree, delivering an average of one candidate every year for the past six years on behalf of its collaborators and clients. Domainex has also utilized its expertise and proprietary technologies to develop its own internal pipeline - focussed on exciting and novel, but challenging drug targets.
Domainex's lead programme targets key kinases (TBK1/IKKe) involved in innate immunity, to develop new disease-modifying drugs against inflammatory indications such as COPD and psoriasis. Domainex's compounds have been demonstrated to be efficacious in in vivo models and we are now quickly progressing to GLP studies.
Domainex has also focussed its capabilities on the development of an epigenetics-targeted pipeline, namely against the protein methyl-transferases (PKMT). Domainex is a leader in PKMT drug discovery and is developing highly potent, selective and drug-like compounds.